Ocugen Inc is a pioneering biopharmaceutical company dedicated to developing innovative gene therapies aimed at curing blindness caused by a variety of diseases. With a focus on genetic eye diseases such as retinitis pigmentosa and leber congenital amaurosis, Ocugen's leading product, OCU400, represents a significant advancement in retinal therapy. The company also explores treatments for age-related macular degeneration and diabetic eye diseases through its diverse pipeline, including OCU410 and OCU200. Ocugen's commitment to eye health extends through strategic partnerships, enhancing its research and development capabilities. Headquartered in Malvern, Pennsylvania, Ocugen strives to bring new hope to individuals suffering from vision loss.
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders. The…
Joel South Wednesday’s top analyst upgrades and downgrades included Baidu, BJ’s Wholesale Club, CrowdStrike, Ocugen, Palo Alto Networks, PayPal, Playtika, Schlumberger, Workday and Zoom Video Communications.
Stocks were indicated down before the opening bell Monday. A couple of meme stocks were bucking the trend, and one acquisition target was soaring.
Meme stocks traded well-mixed at midday Thursday. The morning's most surprising turn came from a stock that missed estimates and gave lower guidance but still traded higher.
U.S. stock markets were having an off-day Tuesday, and the meme stocks were as well -- with the exception of a look-alike to GameStop's position one year ago.
Trading wa light again Thursday, but one meme stock was making some real noise.
AMC stock got a big bump on Friday thanks to a new Spider-Man movie, but Monday's downturn was taking back a small piece of the big gain.
Markets were waiting with bated breath the FOMC announcement. In the meantime, there are always new Elon Musk tweets to ponder.
Several beaten-down meme stocks were getting some love as investors decided that Tuesday was a good day for taking on risk.
Reduced concern for the impact of the Omicron variant of the coronavirus lifted stocks higher on Monday. The effect appeared to be continuing in Tuesday's premarket trading.
Despite Friday's sharp drop in equity prices, there were a couple of winners. Premarket trading indicated a higher open, with crude oil up well over 5%.
Friday's shortened trading session was dominated by the news of a new coronavirus variant and its impact on investors.
An FDA directive has hammered a coronavirus vaccine maker Friday morning as a new variant of the infection is discovered in South Africa.
A strong October jobs report lit a fire under traders in Friday's premarket. One of Thursday's big movers added a bit more Friday morning and another was dropping after reporting earnings.
Why does a coronavirus vaccine maker's stock drop more than 20% after the vaccine is approved for use? It happened Wednesday.
